Physician profile
Andrew C Gin
NPI 1336110717
$5,882.39
in general payments reported to CMS, 2019-2025
36 companies · $349 in 2025
The $349 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $1,129 · 2021: $1,633 · 2022: $1,205 · 2023: $610 · 2024: $486 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,444.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $906.31 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $642.84 | 2021-2025 | Ingrezza, Ongentys |
| Kyowa Kirin, INC. | $516.25 | 2019-2023 | Nourianz |
| Ucb, INC. | $437.08 | 2019-2022 | |
| Allergan, INC. | $396.49 | 2020-2022 | |
| Amgen INC. | $349.45 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $302.69 | 2019-2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $297.92 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $297.23 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $192.07 | 2019-2025 | Crexont, Ongentys, Rytary |
| Lilly USA, LLC | $190.25 | 2019-2024 | Kisunla |
| Pfizer INC. | $149.89 | 2023-2025 | |
| Eisai INC. | $134.50 | 2021-2024 | |
| Acorda Therapeutics, INC | $130.59 | 2020-2023 | Inbrija, Ampyra |
| Corium, LLC | $93.56 | 2022-2023 | Adlarity |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $92.43 | 2021-2023 | |
| Avion Pharmaceuticals | $74.38 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $73.57 | 2023-2024 | Austedo Xr, Ajovy |
| Biohaven Pharmaceutical Holding Company LTD. | $71.26 | 2022 | |
| Novartis Pharmaceuticals Corporation | $67.40 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $61.72 | 2021 | |
| Adamas Pharmaceuticals, INC. | $51.56 | 2020-2021 | |
| Neurelis, INC. | $42.87 | 2020 | |
| Axsome Therapeutics, INC. | $36.17 | 2025 | Symbravo |
| Upsher-Smith Laboratories LLC | $36.07 | 2020-2022 | |
| Lundbeck LLC | $35.16 | 2022-2024 | Vyepti |
| Ge Healthcare | $30.01 | 2020 | |
| Zyla Life Sciences, INC. | $28.28 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $26.26 | 2022 | |
| Abbott Laboratories | $24.71 | 2021 | |
| Biogen, INC. | $21.29 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $19.76 | 2023 | Fycompa |
| Azurity Pharmaceuticals, INC. | $16.89 | 2023 | Horizant |
| Alnylam Pharmaceuticals INC. | $16.66 | 2021 | |
| Argenx US, INC. | $13.90 | 2023 | Vyvgart Hytrulo |
| Sumitomo Pharma America, INC. | $4.92 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Gin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.